FibroGen, Inc. (0IL8.L)
USD 0.29
(8.4%)
USD 0.29
(8.4%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 128.9 Million USD | 7.02% |
| 2022 | 120.45 Million USD | -45.85% |
| 2021 | 222.43 Million USD | 32.84% |
| 2020 | 167.45 Million USD | -34.44% |
| 2019 | 255.43 Million USD | 1216.34% |
| 2018 | -22.88 Million USD | 67.7% |
| 2017 | -70.84 Million USD | -828.68% |
| 2016 | -7.62 Million USD | 77.06% |
| 2015 | -33.26 Million USD | -152.11% |
| 2014 | -13.19 Million USD | -180.15% |
| 2013 | 16.46 Million USD | 298.58% |
| 2012 | -8.28 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 45.46 Million USD | 50.79% |
| 2024 Q1 | 30.14 Million USD | 38.74% |
| 2023 Q3 | 35.89 Million USD | -7.04% |
| 2023 Q4 | 21.73 Million USD | -39.45% |
| 2023 Q1 | 32.67 Million USD | 10.96% |
| 2023 Q2 | 38.61 Million USD | 18.18% |
| 2023 FY | 128.9 Million USD | 7.02% |
| 2022 Q4 | 29.44 Million USD | 157.65% |
| 2022 FY | 120.45 Million USD | -45.85% |
| 2022 Q3 | 11.42 Million USD | -50.31% |
| 2022 Q2 | 22.99 Million USD | -59.36% |
| 2022 Q1 | 56.58 Million USD | 321.74% |
| 2021 FY | 222.43 Million USD | 32.84% |
| 2021 Q2 | 21.28 Million USD | -39.23% |
| 2021 Q4 | 13.41 Million USD | -91.21% |
| 2021 Q3 | 152.7 Million USD | 617.41% |
| 2021 Q1 | 35.02 Million USD | -43.85% |
| 2020 FY | 167.45 Million USD | -34.44% |
| 2020 Q1 | 23.43 Million USD | 231.46% |
| 2020 Q2 | 39.81 Million USD | 69.91% |
| 2020 Q3 | 41.82 Million USD | 5.06% |
| 2020 Q4 | 62.38 Million USD | 49.15% |
| 2019 Q4 | 7.06 Million USD | -78.53% |
| 2019 FY | 255.43 Million USD | 1216.34% |
| 2019 Q3 | 32.93 Million USD | -76.4% |
| 2019 Q2 | 139.55 Million USD | 624.0% |
| 2019 Q1 | -26.63 Million USD | -170.51% |
| 2018 Q3 | -27.41 Million USD | -234.91% |
| 2018 Q4 | 37.77 Million USD | 237.77% |
| 2018 Q1 | -25.04 Million USD | -151.52% |
| 2018 Q2 | -8.18 Million USD | 67.32% |
| 2018 FY | -22.88 Million USD | 67.7% |
| 2017 FY | -70.84 Million USD | -828.68% |
| 2017 Q3 | -23.06 Million USD | -28.25% |
| 2017 Q1 | -19.84 Million USD | -6.13% |
| 2017 Q2 | -17.98 Million USD | 9.36% |
| 2017 Q4 | -9.95 Million USD | 56.82% |
| 2016 FY | -7.62 Million USD | 77.06% |
| 2016 Q4 | -18.69 Million USD | -78.8% |
| 2016 Q3 | -10.45 Million USD | -128.35% |
| 2016 Q2 | 36.88 Million USD | 340.03% |
| 2016 Q1 | -15.36 Million USD | 56.69% |
| 2015 FY | -33.26 Million USD | -152.11% |
| 2015 Q4 | -35.48 Million USD | -9.06% |
| 2015 Q3 | -32.53 Million USD | -147.15% |
| 2015 Q2 | 68.99 Million USD | 301.5% |
| 2015 Q1 | -34.24 Million USD | 2.59% |
| 2014 Q2 | 56.68 Million USD | 829.21% |
| 2014 Q4 | -35.15 Million USD | -30.41% |
| 2014 Q3 | -26.95 Million USD | -147.55% |
| 2014 FY | -13.19 Million USD | -180.15% |
| 2014 Q1 | -7.77 Million USD | 54.39% |
| 2013 Q1 | -12.23 Million USD | 0.0% |
| 2013 Q3 | 48.06 Million USD | 2164.6% |
| 2013 Q2 | -2.32 Million USD | 80.97% |
| 2013 Q4 | -17.04 Million USD | -135.46% |
| 2013 FY | 16.46 Million USD | 298.58% |
| 2012 FY | -8.28 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 99.153% |
| Dynavax Technologies Corporation | 182.11 Million USD | 29.219% |
| Illumina, Inc. | 2.74 Billion USD | 95.302% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 97.54% |
| Biogen Inc. | 7.3 Billion USD | 98.235% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 1447.522% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 94.057% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 88.206% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 75.388% |
| Waters Corporation | 1.76 Billion USD | 92.681% |
| Perrigo Company plc | 1.68 Billion USD | 92.329% |
| uniQure N.V. | 2.21 Million USD | -5719.594% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -644.292% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 64.394% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 41283.387% |
| bluebird bio, Inc. | -4.03 Million USD | 3298.61% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -771.326% |
| Imunon, Inc. | -720 Thousand USD | 18003.209% |
| Myriad Genetics, Inc. | 476.4 Million USD | 72.942% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 93.022% |
| Nektar Therapeutics | 53.47 Million USD | -141.041% |
| Editas Medicine, Inc. | -99.52 Million USD | 229.515% |
| Verastem, Inc. | -62 Thousand USD | 208009.677% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 99.514% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 513.583% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -1183.649% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 754.368% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 93.231% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 384.399% |
| Evolus, Inc. | 140.52 Million USD | 8.27% |
| Adicet Bio, Inc. | -6.09 Million USD | 2213.873% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 251.267% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 98.859% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -76.419% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 96.28% |
| OPKO Health, Inc. | 318.12 Million USD | 59.48% |
| Homology Medicines, Inc. | -7.22 Million USD | 1883.151% |
| Geron Corporation | -123.5 Million USD | 204.373% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 91.508% |
| Exelixis, Inc. | 1.75 Billion USD | 92.666% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 44245.205% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 132.323% |
| Zoetis Inc. | 5.83 Billion USD | 97.79% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 47.286% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -42583.444% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 98.502% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 42642.574% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 83.442% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 72.913% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 79.76% |
| Blueprint Medicines Corporation | 236.58 Million USD | 45.514% |
| Insmed Incorporated | 239.63 Million USD | 46.208% |
| TG Therapeutics, Inc. | 219.1 Million USD | 41.169% |
| Incyte Corporation | 3.44 Billion USD | 96.253% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 62.517% |